Cargando…

Cost-Effectiveness of Brexanolone Versus Selective Serotonin Reuptake Inhibitors for the Treatment of Postpartum Depression in the United States

BACKGROUND: Brexanolone injection (BRX) was approved by the FDA in 2019 for the treatment of adult patients with postpartum depression (PPD), but its cost-effectiveness has not yet been evaluated. OBJECTIVE: To estimate the cost-effectiveness of BRX compared with treatment with selective serotonin r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eldar-Lissai, Adi, Cohen, Joshua T., Meltzer-Brody, Samantha, Gerbasi, Margaret E., Chertavian, Elizabeth, Hodgkins, Paul, Bond, Julia C., Johnson, Scott J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391201/ https://www.ncbi.nlm.nih.gov/pubmed/32191592 http://dx.doi.org/10.18553/jmcp.2020.19306

Ejemplares similares

Brexanolone in Postpartum Depression: Post Hoc Analyses to Help Inform Clinical Decision-Making
por: Gerbasi, Margaret E., et al.
Publicado: (2021)

Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression
por: Cooper, Miranda C., et al.
Publicado: (2019)

Associations between commonly used patient-reported outcome tools in postpartum depression clinical practice and the Hamilton Rating Scale for Depression
por: Gerbasi, Margaret E., et al.
Publicado: (2020)

Open‐label, proof‐of‐concept study of brexanolone in the treatment of severe postpartum depression
por: Kanes, Stephen J., et al.
Publicado: (2017)

Efficacy of brexanolone in postpartum depression
por: Rodríguez Mercado, C. M.
Publicado: (2023)

Brexanolone: panacea for postpartum depression? Reply to: ‘Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?’
por: Shukla, Ajay Kumar, et al.
Publicado: (2021)

Epidemiology of Pediatric Essential Tremor in the United States: A Systematic Literature Review from 2010 to 2020
por: Gerbasi, Margaret E., et al.
Publicado: (2022)

Brexanolone therapeutics in post-partum depression involves inhibition of systemic inflammatory pathways
por: Balan, Irina, et al.
Publicado: (2023)

Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data
por: Garafola, Svetlana, et al.
Publicado: (2023)

Treating Postpartum Depression: What Do We Know about Brexanolone?
por: Ali, Muneeza, et al.
Publicado: (2021)

Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?
por: Faden, Justin, et al.
Publicado: (2020)

Patient-reported perceptions of brexanolone in the treatment of postpartum depression: A qualitative analysis
por: Salwan, Aaron, et al.
Publicado: (2023)

Essential tremor patients experience significant burden beyond tremor: A systematic literature review
por: Gerbasi, Margaret E., et al.
Publicado: (2022)

Brexanolone, a GABA(A) Modulator, in the Treatment of Postpartum Depression in Adults: A Comprehensive Review
por: Edinoff, Amber N., et al.
Publicado: (2021)

Trajectories of Depressive and Anxiety Symptoms Across Pregnancy and Postpartum in Selective Serotonin Reuptake Inhibitor‐Treated Women
por: Mesches, Gabrielle A., et al.
Publicado: (2022)

New insights into perinatal depression: pathogenesis and treatment during pregnancy and postpartum
por: Meltzer-Brody, Samantha
Publicado: (2011)

Allopregnanolone in postpartum depression: Role in pathophysiology and treatment
por: Meltzer-Brody, Samantha, et al.
Publicado: (2020)

Sentiment Analysis of Online Reviews for Selective Serotonin Reuptake Inhibitors and Serotonin–Norepinephrine Reuptake Inhibitors
por: Compagner, Chad, et al.
Publicado: (2021)

Preclinical and clinical pharmacology of brexanolone (allopregnanolone) for postpartum depression: a landmark journey from concept to clinic in neurosteroid replacement therapy
por: Reddy, Doodipala Samba, et al.
Publicado: (2023)

Brexanolone as adjunctive therapy in super‐refractory status epilepticus
por: Rosenthal, Eric S., et al.
Publicado: (2017)

Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
por: Briley, Mike, et al.
Publicado: (2010)

Clinical pharmacology of serotonin selective reuptake inhibitors /
por: Preskorn, Sheldon
Publicado: (1996)

Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia
por: Welsch, Patrick, et al.
Publicado: (2018)

Selective serotonin reuptake inhibitors and Alzheimer’s disease
por: Mdawar, Bernadette, et al.
Publicado: (2019)

Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression
por: James, Gregory M., et al.
Publicado: (2017)

RAVE DRUG (ECSTASY) AND SELECTIVE SEROTONIN REUPTAKE INHIBITOR ANTI-DEPRESSANTS
por: Singh, A.N., et al.
Publicado: (2000)

Rapid response to selective serotonin reuptake inhibitors in post-COVID depression
por: Mazza, Mario Gennaro, et al.
Publicado: (2022)

Serotonin syndrome triggered by postoperative administration of serotonin noradrenaline reuptake inhibitor (SNRI)
por: Takata, Junko, et al.
Publicado: (2019)

Measuring hemophilia caregiver burden: validation of the Hemophilia Caregiver Impact measure
por: Schwartz, Carolyn E., et al.
Publicado: (2017)

A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials
por: Zhong, Zhuoyuan, et al.
Publicado: (2017)

Effect of Serotonin Reuptake Inhibitors on Pulmonary Hemodynamics in Humans
por: Pleym, Hilde, et al.
Publicado: (2011)

Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis
por: Wozniak, Greta, et al.
Publicado: (2011)

Heart Rate Recovery and Selective Serotonin Reuptake Inhibitors
por: Cerit, Levent
Publicado: (2016)

Selective serotonin reuptake inhibitor-induced galactorrhea with hyperprolactinemia
por: Bhattacharjee, Subir, et al.
Publicado: (2021)

Confounding by Indication in Studies of Selective Serotonin Reuptake Inhibitors
por: Lee, Jimin, et al.
Publicado: (2022)

Selective Serotonin Reuptake Inhibitors and Clozapine: Clinically Relevant Interactions and Considerations
por: Edinoff, Amber N., et al.
Publicado: (2021)

Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis
por: Johnson, Chris F, et al.
Publicado: (2022)

The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspring
por: Olivier, J. D. A., et al.
Publicado: (2013)

Depression and the Use of Selective Serotonin Reuptake Inhibitors in Patients with Acute Intracerebral Hemorrhage
por: Syed, Maryam J, et al.
Publicado: (2019)

Effects of Selective Serotonin Reuptake Inhibitor Treatment on Ovarian Reserves in Patients with Depression
por: Gök, Soner, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oq42br6bp6iht9asb2kq01gin2